Cipla, an Indian multinational pharmaceutical and biotechnology company, recently presented a new respiratory inhaler called Synchrobreathe (SB) at the South Africa Thoracic Society (SATS) Annual Conference that took place in Cape Town, South Africa between the 7h and the 10th of August.
The company will soon launch the innovative inhaler, which will offer important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD), asthma and COPD. The new inhaler is a novel, breath-actuated inhaler (BAI) with a dose counter, encouraging patient compliance. The inhaler is simple to use — the inspiratory flow required to trigger the inhaler mechanism is low and eliminates coordination challenges, which is the biggest issue faced by patients using conventional pressurized metered dose inhalers (pMDIs).
Frank Pieters, global head of respiratory for Cipla, said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. SB is attractive for patients as the inhaler is easy to use effectively. Equally importantly, SB will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”
Paul Miller, CEO Cipla Medpro, South Africa added, “South Africa has amongst the highest asthma mortality rates in the world. As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation for the first time to the medical community at the SATS congress. Synchrobreathe will definitely make patients’ lives easier in managing their obstructive airway disease. Synchrobreathe is in line with Cipla’s commitment to bring innovative products and inhalers to best fit physicians’ and patients’ needs, thereby advancing healthcare for all Synchrobreathe is expected to reach the market in the current year.”
Cipla respiratory products are currently available in over 100 countries. The company is one of the world’s largest generic pharmaceutical companies with a strong presence in over 170 countries.
Cipla offers a unique range of inhaled medication and devices that have been developed over the years, for every age and every stage of asthma and COPD. The company holds a portfolio of 27 molecules and combinations across a range of inhalers, and has proven end-to-end competence across respiratory care covering the value chain from API, formulation, development and manufacturing to medical and patient education.